Literature DB >> 1330292

Accessibility to DNA in carcinoma chromatin is promoted by nanomolar okadaic acid: effect on AT-rich DNA binding proteins.

M S Rieber1, M Rieber.   

Abstract

Differential accessibility to DNA in tumor cell chromatin is important to growth, differentiation apoptosis, and the targeting of DNA modifying drugs. We now show that endonuclease accessibility to DNA in the nuclei of A431 human carcinoma cells is increased within 90 min by nontoxic nanomolar levels of okadaic acid, known to inhibit protein phosphatase 2A. This genomic hypersensitivity was partly enhanced by joint treatment with epidermal growth factor and okadaic acid but did not appear without the latter. Nuclei with greater DNA susceptibility showed a decrease in M(r) 80,000 DNA binding protein doublet specific for dAT-rich sequences concurrent with the "apparent" hyperphosphorylation of a M(r) 70,000 nuclear matrix protein. We propose that some of the tumor-promoting effects of okadaic acid may be partly associated with its ability to promote genomic susceptibility.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330292

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Nuclear chromatin texture and sensitivity to DNase I in human leukaemic CEM cells incubated with nanomolar okadaic acid.

Authors:  S Yatouji; F Liautaud-Roger; J Dufer
Journal:  Cell Prolif       Date:  2000-02       Impact factor: 6.831

2.  Different chromatin organization in benign and malignant cells revealed by unequal nuclease sensitivity between tumor and normal cell genomes.

Authors:  Manuel Rieber; Mary Strasberg-Rieber
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

3.  Apoptosis induced in neuronal cultures by either the phosphatase inhibitor okadaic acid or the kinase inhibitor staurosporine is attenuated by isoquinolinesulfonamides H-7, H-8, and H-9.

Authors:  C M Cagnoli; E Kharlamov; C Atabay; T Uz; H Manev
Journal:  J Mol Neurosci       Date:  1996       Impact factor: 3.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.